Using furosemide to assess kidney recovery in critically ill patients on dialysis
A Protocol Based-Furosemide Stress Test to Evaluate Renal Recovery During Continuous Renal Replacement Therapy (FST-STOP): A Randomized Controlled Trial
This study is testing if a special kidney stress test using furosemide can give better information about kidney recovery for critically ill adults on dialysis compared to standard care.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 80 (estimated) |
| Ages | 20 Years and up |
| Sex | All |
| Sponsor | Chiang Mai University Academic / other |
| Locations | 1 site (Chiang Mai) |
| Trial ID | NCT06229990 on ClinicalTrials.gov |
What this trial studies
This clinical trial compares the effectiveness of a furosemide stress test (FST) against standard care in evaluating renal recovery in critically ill patients undergoing continuous renal replacement therapy (CRRT) for acute kidney injury. The study aims to determine if the FST can provide better insights into kidney function recovery compared to traditional methods. Participants will be adults with stage 3 acute kidney injury who have been on CRRT for at least 48 hours. The trial seeks to address the lack of evidence regarding the timing of withholding CRRT and its associated complications.
Who should consider this trial
Good fit: Ideal candidates are adults aged 20 and older with stage 3 acute kidney injury and oliguria who are receiving CRRT in an intensive care setting.
Not a fit: Patients with certain exclusions such as severe electrolyte imbalances, previous chronic kidney disease stage 5, or those on inotropic drugs may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to improved assessment of kidney recovery and potentially reduce complications associated with prolonged CRRT.
How similar studies have performed: While the use of furosemide stress tests has been explored in other contexts, this specific application in critically ill patients undergoing CRRT is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult 20 year of age or older * Acute kidney injury (AKI) stage 3 according to Kidney Disease Improving Global Outcomes (KDIGO) classification with oliguria (urine \<400 ml/day) * Initiate CRRT in ICU (medical ICU, surgical ICU, cardiac care unit) for at least 48 hours (time for initiation and modality of CRRT can adjust by clinician) Exclusion Criteria: * Use any inotropic drug (norepinephrine, epinephrine, dopamine, dobutamine) * Blood urea nitrogen (BUN) \>80 mg/dL * Serum K \<3.5 or \>5 mmol/L * Arterial potential of Hydrogen (pH) \<7.3 * Serum bicarbonate (HCO3) \<15 mmol/L * Urine volume \<400 or \>2,100 mL/day * Urine creatinine clearance (CrCl) at 6 hours \>20 mL/min * Previous chronic kidney disease (CKD) stage 5 or estimated glomerular filtration rate (eGFR) \<15 mL/min/1.73 m2 * Previous RRT within 14 days * Kidney transplantation * Obstructive etiology for AKI * Toxin/drug that necessitates RRT * Allergy to furosemide * Moribund with expected death within 24 hours * Pregnancy
Where this trial is running
Chiang Mai
- Chiang Mai University — Chiang Mai, Thailand (Recruiting)
Study contacts
- Study coordinator: Prit Kusirisin, MD
- Email: jingprit@hotmail.com
- Phone: +66897574028
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.